Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
← catalyst calendarSponsored by Guardant Health, Inc. (industry) · GH — their whole pipeline →. With Premier Research.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
44,467actual
Sites
271
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-10-08 | actual | When the study began enrolling |
| Primary completion | 2024-03-20 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-05 | estimated | The whole study's end, after follow-up |
| First posted | 2019-10-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Colorectal Cancer
Primary outcomes
what the primary-completion date above is the date OFSensitivity of colorectal cancer detection
measured 60 days
Specificity of advanced neoplasia detection
measured 60 days
Publications
- PMID 38477993 — linked by the registry
- PMID 38477985 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · GH's whole pipeline · Catalyst calendar · Every registered study · What changed